Skin B-cell lymphoma (CBCL), a group of unique lymphomas with lymphoma neoplasia in cutaneous lymphoma. Skin lesions occur in the head, neck, torso, and lower extremities, and the lesion can be single, multiple, or generalized red or purplish red papules, nodules, or plaques that last for months or years. CBCL can be divided into primary skin B-cell lymphoma and secondary skin B-cell lymphoma. Primary CBCL can be cured by local radiotherapy or resection, and the prognosis is good. The cause is unknown. In the past, CBCL was attributed to reticulocyte sarcoma or reticulocyte disease due to lack of enzyme cytochemistry, immunology, and electron microscopy. In recent years, the development of immunology, which is considered to be a type of cutaneous lymphoma. 1. Skin lesions occur in the head, neck, trunk and lower limbs, and mucous membranes can also be affected. The skin damage of CBCL is mostly secondary (67.5%), but it can also be primary (33.5%).
2. Clinical manifestations vary. The damage can be single, multiple, or generalized. Commonly large nodules or plaques, the color is red, blue, purple or brown, sometimes forming ulcers; also see red maculopapular rash; occasionally subcutaneous mass. Compared with T-cell lymphoma, CBCL usually has no scaly or erythroderma lesions. Laboratory examination
Hemoglobin is reduced; white blood cell count is reduced. It is worth noting that the white blood cells of the early patients are not necessarily reduced, but most of them have different degrees of hemoglobin reduction, which has certain implications for diagnosis. Protein electrophoresis assay showed an increase in α2 globulin, an increase in beta globulin, and an increase in gamma globulin. The immunoglobulin assay increased the IgG and IgM of the LP type; the lactate dehydrogenase assay increased; the alkaline phosphatase assay was normal.
2. Histopathological examination
Almost all low-grade CBCL, including CLL, PL (IC) and CBCC type tumor cells, are infiltrated or diffusely infiltrated by B cells, that is, th
